# Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older

> **NCT00760617** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 526 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK Bio's influenza vaccine GSK2186877A
- **BIOLOGICAL:** Fluarix

## Key facts

- **NCT ID:** NCT00760617
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-06
- **Primary completion:** 2009-05-15
- **Final completion:** 2009-05-15
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00760617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00760617, "Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00760617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*